🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CSPC Megalith Biopharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with CSPC Megalith Biopharmaceutical as lead sponsor. Synced 26 Sep 2026
13Current trials
9Recruiting now
14Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CSPC Megalith Biopharmaceutical is the lead sponsor of 13 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Bevacizumab, SYS6010 and SYS6023. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting969%
  • Not yet open323%
  • Active, closed18%

Trials by phase

  • Phase 1/2538%
  • Phase 2431%
  • Phase 1323%
  • Phase 318%
01

Clinical trials sponsored by CSPC Megalith Biopharmaceutical

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
NCT07744763 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Recruiting 2025-03 China
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
NCT07597629 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
Drugs: KN026, SYS6023
Phase 2 Recruiting 2026-05 China
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
NCT07254585 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting 2025-12 China
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
NCT07415863 · ClinicalTrials.gov ↗ · Advanced/Metastatic Solid Tumors
Drug: SYS6043
Phase 1/2 Recruiting 2024-12 China
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
NCT07110883 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: SYS6023
Phase 1 Recruiting 2024-08 China
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
NCT06958679 · ClinicalTrials.gov ↗ · B-cell Malignancies, Solid Tumors
Phase 1 Recruiting 2025-04 China
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
NCT07714668 · ClinicalTrials.gov ↗ · Ovarian Cancer, Recurrent Ovarian Cancer
Phase 2 Recruiting 2026-08 China
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
NCT06970795 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Other Advanced Solid Tumors
Phase 1 Recruiting 2025-04 China
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
NCT06927986 · ClinicalTrials.gov ↗ · EGFR-mutated Locally Advanced or Metastatic NSCLC
Phase 3 Recruiting 2025-03 China
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions
NCT07702656 · ClinicalTrials.gov ↗ · High-grade Cervical Intraepithelial Lesions
Phase 2 Not yet open 2026-07 China
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
NCT07750041 · ClinicalTrials.gov ↗ · Unresectable Advanced or Metastatic Colorectal Cancer
Phase 1/2 Not yet open 2026-08 China
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
NCT07761286 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
Phase 1/2 Not yet open 2026-09 China
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
NCT07122063 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Active, closed 2025-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in CSPC Megalith Biopharmaceutical trials

14 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in CSPC Megalith Biopharmaceutical trials

15 conditions
Advanced Solid Tumors2Advanced Breast Cancer1Head and Neck Squamous Cell Carcinoma1High-grade Cervical Intraepithelial Lesions1Advanced/Metastatic Solid Tumors1Unresectable Advanced or Metastatic Colorectal Cancer1Advanced Solid Tumor1B-cell Malignancies1Solid Tumors1Ovarian Cancer1Recurrent Ovarian Cancer1Small Cell Lung Cancer1Other Advanced Solid Tumors1HCC - Hepatocellular Carcinoma1EGFR-mutated Locally Advanced or Metastatic NSCLC1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China139

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about CSPC Megalith Biopharmaceutical trials

How many clinical trials does CSPC Megalith Biopharmaceutical sponsor?

CSPC Megalith Biopharmaceutical is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are CSPC Megalith Biopharmaceutical trials recruiting?

Yes. 9 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is CSPC Megalith Biopharmaceutical testing?

Its current trials name 14 drugs and biologicals as interventions. The most frequent are Bevacizumab (2), SYS6010 (2), SYS6023 (2), SYS6043 (2) and SYS6090 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.